Wegovy Maker Faces Potential Tariff Challenge Amid U.S.-EU Tensions
Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on the EU. Despite this, CEO Lars Fruergaard Jorgensen remains optimistic about the company's strategic positioning, emphasizing its resilience in the current economic climate.
- Country:
- United Kingdom
Wegovy's manufacturer, Novo Nordisk, may face hurdles as President Donald Trump targets the European Union with potential tariffs. However, the company's CEO expresses confidence in their market strategy.
Speaking to journalists outside Copenhagen, CEO Lars Fruergaard Jorgensen addressed concerns following the latest business earnings report.
The CEO underlined Novo Nordisk's robust positioning, despite the impending threat of tariffs, highlighting their preparedness for potential economic disruptions.
ALSO READ
-
EU Firms Rethink Supply Chains as Geopolitical Risks Reshape Global Trade
-
Trade War Chessboard: Agriculture, Energy, and Rare Earths in Focus
-
Trump and Xi Set for High-Stakes Summit: Trade, Taiwan, and Technology in Focus
-
US Tariff Announcement Delay Amidst Xi-Trump Summit
-
India Defends Energy Policy Amidst Rising Tariff Threats from U.S.
Google News